Paper Details

  1. Home
  2. Paper Details

Low Persistence Rates in Patients With Rheumatoid Arthritis Treated With Triple Therapy and Adverse Drug Events Associated With Sulfasalazine.

Author: CannonGrant W, CurtisJeffrey R, ErhardtDaniel P, MikulsTed R, SauerBrian C, TengChia-Chen

Observational StudyResearch that observes and collects data on participants' behavior and outcomes in their natural state, without intervention.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, N.I.H., ExtramuralResearch funding provided by the NIH to external research institutions and researchers.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
Research Support, U.S. Gov't, Non-P.H.S.Research funding provided by US government agencies other than the Public Health Service.

Overview

This study examined persistence and adherence rates of two combination therapies for rheumatoid arthritis (RA) in US veterans. The therapies involved adding a tumor necrosis factor inhibitor (TNFi) or adding sulfasalazine (SSZ) and hydroxychloroquine to methotrexate (MTX) (triple therapy). The study also reported reasons for discontinuation of treatment in each group.
Paper Details　
Original Abstract of the Article :
Combination treatments for patients with rheumatoid arthritis (RA) with an inadequate response to methotrexate (MTX) alone include the addition of a tumor necrosis factor inhibitor (TNFi) or the addition of sulfasalazine (SSZ) and hydroxychloroquine to MTX (triple therapy). We compared persistence a...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1002/acr.23759

データ提供：米国国立医学図書館（NLM）

Rheumatoid Arthritis Treatment: Finding the Right Path in a Desert of Symptoms

Navigating the harsh and often relentless desert of rheumatoid arthritis (RA) can be a challenging journey. This research focuses on the treatment of RA, specifically examining the effectiveness of different combination therapies. The researchers compared the persistence and adherence rates of two common combination treatments: triple therapy, which includes methotrexate (MTX), sulfasalazine (SSZ), and hydroxychloroquine, and TNF inhibitor therapy, which combines MTX with a TNF inhibitor.

A Complex Landscape: Finding the Right Treatment for RA

This study reveals the complexity of treating RA, demonstrating that different combination therapies have varying levels of effectiveness and adherence. The researchers found that persistence rates were lower in patients treated with triple therapy compared to TNF inhibitor therapy. These findings underscore the importance of considering individual patient needs and tailoring treatment plans accordingly.

Navigating the Desert: Managing RA and Side Effects

This research highlights the need for careful monitoring of patients with RA, particularly those receiving triple therapy. Understanding the potential side effects of different medications and addressing them promptly can help improve patient adherence and ultimately lead to better outcomes. This research encourages healthcare providers to work closely with patients to develop personalized treatment plans that optimize effectiveness and minimize side effects.

Dr.Camel's Conclusion

This research reminds us that the desert of RA is full of complex challenges. Finding the right treatment path for each patient requires careful consideration of individual needs and preferences. This study underscores the importance of ongoing research and collaboration to develop more effective and personalized therapies for RA, ultimately helping individuals find relief from this debilitating condition.

Date :
  1. Date Completed 2020-04-08
  2. Date Revised 2020-12-16
Further Info :

Pubmed ID

30221485

DOI: Digital Object Identifier

10.1002/acr.23759

Related Literature

Article Analysis
・Side Effects of sulfasalazine
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.